Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 370

1.

Phase II trials in journal of clinical oncology.

Cannistra SA.

J Clin Oncol. 2009 Jul 1;27(19):3073-6. doi: 10.1200/JCO.2009.23.1811. Epub 2009 May 18. No abstract available.

PMID:
19451415
2.

Examining heterogeneity in phase II trial designs may improve success in phase III.

Tuma RS.

J Natl Cancer Inst. 2008 Feb 6;100(3):164-6. doi: 10.1093/jnci/djn006. Epub 2008 Jan 29. No abstract available.

PMID:
18230788
3.

Improving the design of phase II trials of cytostatic anticancer agents.

Stone A, Wheeler C, Barge A.

Contemp Clin Trials. 2007 Feb;28(2):138-45. Epub 2006 Jul 14. Review.

PMID:
16843736
4.

Newer phase II trial designs gaining ground.

Benowitz S.

J Natl Cancer Inst. 2007 Oct 3;99(19):1428-9. Epub 2007 Sep 25. No abstract available.

PMID:
17895467
5.

Optimizing randomized phase II trials assessing tumor progression.

Stone A, Wheeler C, Carroll K, Barge A.

Contemp Clin Trials. 2007 Feb;28(2):146-52. Epub 2006 May 19.

PMID:
16807129
6.

Optimising the design of phase II oncology trials: the importance of randomisation.

Ratain MJ, Sargent DJ.

Eur J Cancer. 2009 Jan;45(2):275-80. doi: 10.1016/j.ejca.2008.10.029. Epub 2008 Dec 6.

PMID:
19059773
7.

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

Rubinstein LV, Dancey JE, Korn EL, Smith MA, Wright JJ.

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. Epub 2007 Sep 25. No abstract available.

PMID:
17895470
8.

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

El-Maraghi RH, Eisenhauer EA.

J Clin Oncol. 2008 Mar 10;26(8):1346-54. doi: 10.1200/JCO.2007.13.5913. Epub 2008 Feb 19. Review.

PMID:
18285606
9.

Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.

Suman VJ, Dueck A, Sargent DJ.

Cancer Invest. 2008 Jun;26(5):439-44. doi: 10.1080/07357900801971057. Review. No abstract available.

PMID:
18568764
10.

Criticism of tumor response criteria raises trial design questions.

Twombly R.

J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. No abstract available.

PMID:
16478740
11.

[A combination phase I/II study--dose escalation plan].

Yamamoto N.

Gan To Kagaku Ryoho. 2000 Dec;27(14):2267-74. Review. Japanese.

PMID:
11142175
12.

[Characteristics of clinical trials in oncology: pharmacist's implication].

Madelaine-Chambrin I.

Ann Pharm Fr. 2006 Jan;64(1):36-42. Review. French.

PMID:
16449936
13.

Randomized phase II trials: misleading and unreliable.

Stewart DJ.

J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20. No abstract available.

PMID:
20855829
14.

[Randomizations!].

Piedbois P, Buyse M.

Cancer Radiother. 1998 Dec;2(6):663-4. French. No abstract available.

PMID:
9922769
15.

Development of growth inhibitory agents in urological and other malignancies.

Stadler WM.

BJU Int. 2006 Sep;98(3):497-502. Epub 2006 Jul 7. Review. No abstract available.

16.

Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.

Ratain MJ, Karrison TG.

Clin Cancer Res. 2007 Feb 1;13(3):781-2. No abstract available.

17.

Design of phase I and II clinical trials in oncology and ethical issues involved.

Goh BC.

Ann Acad Med Singapore. 2000 Sep;29(5):588-97. Review.

PMID:
11126693
18.

Five-year change in statistical designs of phase II trials published in leading cancer journals.

Thezenas S, Duffour J, Culine S, Kramar A.

Eur J Cancer. 2004 May;40(8):1244-9.

PMID:
15110889
19.

Reactive oxygen species may have antitumor activity in metastatic melanoma.

Tuma RS.

J Natl Cancer Inst. 2008 Jan 2;100(1):11-2. Epub 2007 Dec 25. No abstract available.

PMID:
18159075
20.

[Recent proposals for early stage clinical trials of cancer].

Ohashi Y.

Gan To Kagaku Ryoho. 1994 Oct;21 Suppl 3:292-4. Review. Japanese.

PMID:
7986106

Supplemental Content

Support Center